Communications and Marketing

“Lightning protectors” protect cells from oxidative damage

No. 08c | 08/02/2018 | by Eze/Koh

Scientists from the German Cancer Research Center (DKFZ) have been able to unravel how acetylcysteine, a well-known agent used as a cough medication, can protect cells from oxidative stress. In the cell, the substance is rapidly transformed into so-called persulfides. These sulfur compounds unfold their protective effect on the cell by diverting oxidation very efficiently towards themselves, similar to a lightning protector.

© Tobias Dick/DKFZ

Acetylcysteine (also known as N-acetyl cysteine, or NAC) is a well-known non-prescription cough medicine available in any pharmacy. Another, less widely known use of this agent is as an antidote in the treatment of paracetamol (acetaminophen) overdose, which can lead to severe liver damage. If given in time in these cases, acetylcysteine can prevent the worst damage from happening.

Acetylcysteine is generally credited to have cell protection and antioxidative effects, which has been confirmed in numerous experiments. Acetylcysteine reduces the level of endogenous cellular oxidants and lessens the toxic effect of oxidizing exogenous substances. Therefore, acetylcysteine is one of the most commonly used antioxidants in experimental biomedical research.

However, little has been understood so far about exactly how acetylcysteine unfolds its antioxidative effect. A previous hypothesis saying that its effect is based on a direct reaction with oxidants has not been confirmed. Even though acetylcysteine is so widely used, the mechanisms behind its mode of action have remained largely in the dark.

Researchers at the DKFZ have now found a completely new explanation for acetylcysteine’s antioxidative and cell protection effect. In their study, the investigators traced the breakdown of the compound in human cells and noticed that acetylcysteine is converted into hydrogen sulfide. Hydrogen sulfide is known to be a very toxic gas, but it is also known by now that endogenous hydrogen sulfide fulfills physiological functions.

In fact, levels of hydrogen sulfide produced from acetylcysteine do not become toxic, because it is swiftly transformed into another type of sulfur compounds called persulfides. Their function in the cell is largely unknown to date. The findings by the DKFZ researchers suggest that persulfides are the true antioxidative agents. Treatment of cells with synthetic persulfides mimicked the antioxidative effects of acetylcysteine, even at substantially lower levels. “Persulfides bind to proteins and protect them, presumably by diverting oxidation towards themselves, similar to a lightning protector,” said DKFZ’s Tobias Dick, who has led the study.

“We now understand much better how acetylcysteine can protect cells from oxidative stress,” said Daria Ezerina, PhD student and first author of the study. “But this should not lead one to conclude that it would be a good idea to take acetylcysteine as a dietary supplement long-term and at high doses. Because tumor cells under stress might also benefit from this cell protection.” A couple of years ago, cancer researchers in Sweden already showed that long-term administration of acetylcysteine can promote tumor growth and metastasis in mice.

Ezerina D, Takano Y, Hanaoka K, Urano Y, Dick TP (2018) N-acetyl cysteine functions as a fast-acting antioxidant by triggering intracellular H2S and sulfane sulfur production.
Cell Chemical Biology, doi:10.1016/j.chembiol.2018.01.011

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.


Subscribe to our RSS-Feed.

to top